Drug Library Category

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

CNS Drugs DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, bioanalytical, metabolite profiling, and biomarker-related support for central nervous system (CNS) drug research. This section of our drug library helps researchers explore analytical service options for antidepressants, antipsychotics, antiepileptic drugs, antitussives, and related CNS compounds.

CNS drug studies present unique analytical challenges — including blood-brain barrier distribution, low systemic and tissue-level concentrations, active CNS metabolites, and matrix-specific method requirements. Depending on the drug class and study objective, researchers may need to evaluate plasma-to-brain exposure ratios, cerebrospinal fluid concentrations, neurotransmitter-related biomarkers, or receptor-pathway readouts.

Explore CNS Drug Classes Discuss Your Study

Brain Exposure EntryStart from plasma, CSF, or brain tissue concentration questions for CNS drug candidates.

BBB & Matrix-AwareConnect exposure data with blood-brain barrier penetration, CNS distribution, and matrix-specific bioanalysis.

Neurotransmitter-LinkedAlign parent drug and metabolite data with receptor pathway and neurotransmitter-related readouts.

CNS Study Logic

🧠

Parent Drug / Drug ClassAntidepressants, antipsychotics, antiepileptic drugs, antitussives

🧪

Active Metabolites & CNS FormsActive CNS metabolites, receptor-active forms, biotransformation products

📈

Brain & CSF ExposurePlasma concentration, brain tissue distribution, CSF levels, plasma-to-brain ratios

🧬

CNS ResponseNeurotransmitter-related markers, receptor pathway readouts, CNS activity indicators

Explore Subcategories

Navigate CNS Drug Classes

Use these entry points to move from the broad CNS category into more specific drug classes and analytical support pages.

😊

Antidepressants

Bioanalytical support for SSRIs, SNRIs, TCAs, and other antidepressants where parent drug, active metabolite, and CNS exposure data are relevant.

FluoxetineSertralineVenlafaxineAmitriptyline

Explore Antidepressants →

🧩

Antipsychotics

Quantification and metabolite analysis for antipsychotic compounds where plasma-to-brain exposure, receptor occupancy context, and metabolite profiling may guide study design.

RisperidoneOlanzapineQuetiapineAripiprazole

Explore Antipsychotics →

⚡

Antiepileptic Drugs

DMPK and bioanalytical support for antiepileptic drugs where CNS distribution, active metabolites, drug-drug interactions, and low-level quantification may be required.

Valproic AcidLevetiracetamLamotrigineCarbamazepine

Explore Antiepileptic Drugs →

🫁

Antitussives

Analytical services for antitussive compounds including CNS-active cough suppressants where parent drug, active metabolite, and CNS exposure assessment may be needed.

DextromethorphanCodeineBenzonatate

Explore Antitussives →

Common Research Questions

What CNS Drug Researchers Need to Resolve

CNS DMPK projects often start with a matrix- and exposure-specific question. These questions determine whether the workflow should emphasize brain penetration, CSF analysis, low-level quantification, active CNS metabolite profiling, or neurotransmitter-linked biomarkers.

Brain exposure needed?Does the study require brain tissue homogenate, CSF concentration, or plasma-to-brain ratio data beyond systemic exposure?

Blood-brain barrier?Is BBB penetration data relevant, and should brain-to-plasma concentration ratios inform the analytical strategy?

Active CNS metabolites?Should the workflow include active CNS metabolites, neurotransmitter-active forms, or biotransformation products?

Low-level quantification?Are concentrations in brain, CSF, or specific CNS matrices expected to be low, requiring high-sensitivity methods?

Matrix-specific method?Do brain homogenate, CSF, microdialysate, or other CNS-specific matrices require method development different from standard plasma assays?

Receptor-pathway readouts?Are neurotransmitter levels, receptor-pathway markers, or CNS activity-related biomarkers needed alongside exposure data?

Exposure • Mechanism • Response

Connecting CNS Drug Exposure with Brain Distribution and Effect

CNS drug studies need to address not just parent-drug concentration but also whether the compound reaches the brain, how it distributes across CNS compartments, and whether active metabolites or receptor-pathway changes are associated with exposure.

Exposure LayerParent drug, active CNS metabolites, plasma-to-brain ratio, CSF concentration

→

Mechanism LayerNeurotransmitter modulation, receptor binding, ion channel regulation, synaptic signaling

Disposition ContextBBB penetration, CNS tissue distribution, CYP metabolism, transporter-mediated efflux

→

Response LayerNeurotransmitter-related markers, receptor-pathway readouts, CNS activity indicators

Analytical NeedLow-level LC-MS/MS quantification, MetID, BBB-distribution assessment, matrix-specific methods

→

Study InterpretationBrain exposure-response context, CSF–plasma relationships, CNS-specific PK/PD support

The analytical question in CNS research is often not just "how much drug is in plasma," but whether the measured exposure reflects brain penetration, CSF distribution, active CNS metabolites, and receptor- or neurotransmitter-linked changes.

Example CNS Contexts and Readouts

Research Focus	Potential Readouts
Antidepressant studies	Parent drug, active metabolites, neurotransmitter-related markers (serotonin, norepinephrine), brain-to-plasma exposure ratio
Antipsychotic research	Parent drug, active metabolites, dopamine/glutamate pathway markers, brain tissue and CSF concentration
Antiepileptic drug analysis	Parent drug, active metabolites, low-level brain or CSF quantification, DDI-related readouts
CNS distribution and BBB studies	Plasma concentration, brain homogenate quantification, CSF levels, brain-to-plasma ratios
Neurotransmitter and receptor pathways	Neurotransmitter levels, receptor-pathway indicators, CNS activity-related readouts

Bioanalytical and DMPK Service Capabilities

Service Modules for CNS Drug Studies

These service modules connect CNS research questions with analytical routes suited for brain and CSF matrices, low-level quantification, active CNS metabolites, and blood-brain barrier distribution assessment.

Parent Drug and Active CNS Metabolite Quantification

Low-level targeted quantification of CNS parent drugs, active metabolites, and pro-drug forms in plasma, CSF, and brain-derived matrices.

Parent-drug measurement
Active CNS metabolite quantification
Plasma-to-brain ratio analysis
Multi-matrix assay development

LC-MS/MS Quantification Parent-Metabolite Panels

Brain and CSF Exposure Assessment

Analytical support for CNS exposure across matrices where brain penetration, CSF–plasma relationships, and tissue distribution are relevant.

Plasma and serum PK analysis
Brain tissue exposure
CSF concentration profiling
Brain-to-plasma ratio assessment

Plasma & Serum Quantification Complex Biological Matrices

CNS Metabolite Identification

Clarify CNS-specific biotransformation, active-metabolite generation, and CYP-mediated metabolism relevant to brain pharmacokinetics.

Active CNS metabolite confirmation
Phase I / II metabolite support
Neurotransmitter-active metabolite profiling
CYP-related metabolism in CNS context

Metabolite Identification Phase I / II Metabolites

Low-Level and Matrix-Specific Method Development

Custom method development for low-concentration analytes in challenging CNS matrices including brain homogenate, CSF, and microdialysate.

Low-concentration method optimization
Matrix-specific sample preparation
High-sensitivity LC-MS/MS workflows
Challenging CNS matrix support

Custom LC-MS/MS Method Challenging Compounds & Matrices

Integrated Analysis

Why CNS Drug Studies Require Integrated Analysis

CNS drugs face distinct analytical challenges — from BBB penetration and compartmental distribution to low-level quantification and neurotransmitter-linked interpretation. A useful workflow should connect the drug class with the right matrices, exposure context, and CNS-specific readouts.

From CNS drug class to study-ready workflow

🧠

Drug classAntidepressant, antipsychotic, antiepileptic, antitussive, or proprietary CNS compound.

🧪

Relevant analyte setParent drug, active CNS metabolite, neurotransmitter-linked marker, or receptor-pathway readout.

📍

Matrix and exposure contextPlasma, CSF, brain homogenate, microdialysate, or study-specific CNS matrix.

📊

Analytical outputQuantitative exposure data, brain-to-plasma ratios, CNS metabolite profiles, or neurotransmitter-linked interpretation.

Antidepressants

May require parent and active metabolite measurement, neurotransmitter-linked markers, and brain or CSF exposure assessment.

Antipsychotics

Often involve plasma-to-brain ratio assessment, active metabolite profiling, and receptor-pathway-related biomarker context.

Antiepileptic drugs

Can require low-level brain or CSF quantification, active metabolite discrimination, DDI risk assessment, and matrix-specific method development.

Antitussives

May involve CNS-active parent and metabolite quantification, brain exposure profiling, and metabolite-linked CNS activity assessment.

CNS DMPK Support Spanning Drug Classes and Analytical Workflows

Creative Proteomics provides integrated bioanalytical and DMPK services across antidepressants, antipsychotics, antiepileptic drugs, antitussives, and other CNS drug classes — from brain-exposure quantification and CSF analysis to CNS metabolite profiling and neurotransmitter-linked interpretation.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →

CNS Drugs DMPK and Bioanalytical Services

Navigate CNS Drug Classes

Antidepressants

Antipsychotics

Antiepileptic Drugs

Antitussives

What CNS Drug Researchers Need to Resolve

Connecting CNS Drug Exposure with Brain Distribution and Effect

Example CNS Contexts and Readouts

Service Modules for CNS Drug Studies

Parent Drug and Active CNS Metabolite Quantification

Brain and CSF Exposure Assessment

CNS Metabolite Identification

Low-Level and Matrix-Specific Method Development

Why CNS Drug Studies Require Integrated Analysis

From CNS drug class to study-ready workflow

Antidepressants

Antipsychotics

Antiepileptic drugs

Antitussives

CNS DMPK Support Spanning Drug Classes and Analytical Workflows

Need Support for a Specific CNS Drug?

Ready to Quantify Your Lead Compound or Metabolite?